课题基金 / 基金详情

NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS

NU 98X3: IRINOTECAN (CPT-11) AND GEMCITABINE IN PATIENTS WITH SOLID TUMORS
NU 98X3：伊立替康 (CPT-11) 和吉西他滨治疗实体瘤患者
批准号：
7604237
负责人：
AL B BENSON
金额：
$0.59万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7604237
关键词：
NU98X3IRINOTECANCPT11

项目摘要

项目成果

AL B BENSON的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study involves treatment with two intravenous chemotherapy drugs: Irinotecan (CPT-11) and Gemcitabine. While both drugs have been utilized separately for the treatment of a wide variety of cancers, the best dose and schedule has yet to be determined when using them together. The purpose of this study is to discover the highest dose of CPT-11 that can be given safely with Gemcitabine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making
Northwestern University Lead Academic Participating Site, GY4 Supplemental Request
Northwestern University Lead Academic Participating Site
Northwestern University Lead Academic Participating Site
海外基金